Noncoding RNAs in COVID-19 and COVID-19 Related Kidney Dysfunction

The Role of Noncoding RNAs in COVID-19 and COVID-19 Associated Acute Kidney Injury (MiRCOVID)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04381351

Acronym

MiRCOVID

Enrollment

Registered

2020-05-08

Start date

2020-04-16

Completion date

2021-07-31

Last updated

2020-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Keywords

acute kidney injury (AKI), organ dysfunction

Brief summary

In this study, critically ill patients with highly suspected or confirmed COVID-19 will be included. Main goal is the identification of noncoding RNAs in COVID-19 associated organ dysfunction with an emphasis on acute kidney injury.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* COVID-19

Exclusion criteria

* kidney transplantation * eGFR \< 30 ml/Min * dialysis within last 90 days * chronic dialysis * pregnancy

Design outcomes

Primary

Measure	Time frame
predicitive value of noncoding RNAs in COVID-19 associated organ dysfunction	12 months

Countries

Germany

Outcome results